Research output per year
Research output per year
Personal profile
Headline
ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
Biography
Fingerprint
Dive into the research topics where Joshua Brody is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities
Fiore, D., Cappelli, L. V., Zhaoqi, L., Kotlov, N., Sorokina, M., Phillip, J., Zumbo, P., Yoffe, L., Ghione, P., Wang, A., Han, X., Taylor, A., Chiu, W., Fragliasso, V., Tabbo, F., Zamponi, N., Di Siervi, N., Kayembe, C., Medico, G. & Patel, R. P. & 57 others, , 15 Apr 2025, In: Cell Reports Medicine. 6, 4, 102029.Research output: Contribution to journal › Article › peer-review
-
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
Falchi, L., Hutchings, M., Carlo-Stella, C., Morschhauser, F., Dickinson, M., Cartron, G., Khan, C., Tani, M., Martinez-Lopez, J., Bartlett, N. L., Salar, A., Brody, J. D., Leppä, S., Berthier, A., Kallemeijn, M., Relf, J., Tchaleu, F. B., Lundberg, L. & Bachy, E., Apr 2025, In: Haematologica. 110, 4, p. 999-1004 6 p.Research output: Contribution to journal › Letter › peer-review
-
Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation
Hou, X., Wang, C., Zhong, Y., Wang, L., Kang, D. D., Lubitz, G., Xue, Y., Liu, Z., Wang, S., Li, H., Tian, M., Cao, D., Guo, K., Deng, B., McComb, D. W., Marron, T. U., Brown, B. D., Merad, M., Brody, J. D. & Dong, Y., 10 Jun 2025, In: Journal of Controlled Release. 382, 113684.Research output: Contribution to journal › Article › peer-review
-
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, 10 Apr 2025, In: Blood. 145, 15, p. 1621-1631 11 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
High-parameter T-cell spectral phospho-flow-cytometry
Pantsulaia, G. & Brody, J., 2025, (Accepted/In press) In: Methods in Cell Biology.Research output: Contribution to journal › Article › peer-review
Press/Media
-
-
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1/08/24
1 item of Media coverage
Press/Media
-
Preliminary Analysis Of Data Evaluating Investigational Epcoritamab (Duobody® Cd3xcd20) Combination Demonstrates 95% Overall Response Rate In Patients With Previously Untreated Follicular Lymphoma
2/06/24 → 3/06/24
15 items of Media coverage
Press/Media
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
2/06/24 → 3/06/24
3 items of Media coverage
Press/Media
-
Ready-to-go T cells may be responsible for immunotherapy success in classical Hodgkin lymphoma
4/04/24
1 item of Media coverage
Press/Media